Twelve weeks of Janssen’s Olysio (simeprevir) and Gilead Sciences’ Sovaldi (sofosbuvir) boasted near-perfect cure results in a recent trial treating people with genotype 1 of hepatitis C virus (HCV) who did not have cirrhosis. Additionally, some subgroups of those treated for eight weeks had high cure rates, including those with genotype 1b.
continue reading at: hepmag.com/articles/OPTIMIS...
